Company intelligence / Profile preview

RestoriT

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

RestoriT is a biotechnology company focused on developing novel small molecule therapeutics to address sleep disorders and circadian rhythm disruptions. The company's lead research centers on restoring natural sleep patterns by targeting specific biological pathways involved in the sleep-wake cycle. RestoriT aims to provide safer and more effective alternatives to traditional sedative-hypnotics, which often carry risks of dependency and cognitive impairment. By leveraging insights into chronobiology, the company is positioning itself to treat conditions such as chronic insomnia and shift work sleep disorder.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

5 assets

QPD101

Preclinical

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on RestoriT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RestoriT.

Explore the full profile